DC Chemicals Limited
China
Product Name: Ximelagatran
Price: $800.0/100mg $1600.0/250mg $3200.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

192939-46-1

192939-46-1 structure

Name: ximelagatran
Chemical Name: ximelagatran
CAS Number: 192939-46-1
Molecular Formula: C₂₄H₃₅N₅O₅
Molecular Weight: 473.565
Catalog: Signaling Pathways Metabolic Enzyme/Protease Thrombin
Create Date: 2018-04-11 08:00:00
Modify Date: 2024-01-13 18:47:27
Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics[1][2].

Name	ximelagatran
Synonyms	ximelagatran ximelagatra Ethyl N-{(1R)-1-cyclohexyl-2-[(2S)-2-{[4-(N-hydroxycarbamimidoyl)benzyl]carbamoyl}-1-azetidinyl]-2-oxoethyl}glycinate Exanta H-376/95 H 376-95 [14C]-Ximelagatran Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate H 376/95 [3H]-Ximelagatran Ximelagatran (JAN/USAN/INN) Exanta (TN) Exarta Ethyl N-{(1R)-1-cyclohexyl-2-[(2S)-2-{[4-(N'-hydroxycarbamimidoyl)benzyl]carbamoyl}azetidin-1-yl]-2-oxoethyl}glycinate Glycine, N-[(1R)-1-cyclohexyl-2-[(2S)-2-[[[[4-[(hydroxyamino)iminomethyl]phenyl]methyl]amino]carbonyl]-1-azetidinyl]-2-oxoethyl]-, ethyl ester Ximelagatran [USAN:INN] ethyl 2-[[(1R)-1-cyclohexyl-2-[(2S)-2-[[4-[(Z)-N'-hydroxycarbamimidoyl]phenyl]methylcarbamoyl]azetidin-1-yl]-2-oxoethyl]amino]acetate

Description	Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics[1][2].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Thrombin
In Vitro	Ximelagatran is an orally administered direct thrombin inhibitor under development as an anticoagulant agent for prophylaxis against and treatment of thromboembolism. Ximelagatran is rapidly absorbed and quickly converted into its active form Melagatran, a reversible, active-site inhibitor of both free and clot-bound thrombin that has stable and reproducible pharmacokinetic properties. Initial studies have shown Ximelagatran to have good efficacy and safety in the prevention of venous thromboembolism after total knee or total hip replacement[3].
References	[1]. Colwell CW Jr, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003 Oct;1(10):2119-30. [2]. Gao JH, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine (Baltimore). 2017 Oct;96(40):e8059. [3]. Francis CW, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30;349(18):1703-12.

Density	1.4±0.1 g/cm3
Molecular Formula	C₂₄H₃₅N₅O₅
Molecular Weight	473.565
Exact Mass	473.263824
PSA	143.85000
LogP	2.08
Index of Refraction	1.635